Ongoing Pelareorep Clinical Studies

Programs Combination Indication Preclinical Phase 1 Phase 2 Phase 3 Milestone
Breast Cancer
BRACELET-1
Bavencio mBC (HR+/HER2-)
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Fully Enrolled Q2 2022
AWARE-1
Tecentriq Early stage BC
Window of Opportunity Study Preclinical Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started
Biomarker Data Reported H2 2021
IRENE
Retifanlimab* TNBC
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Phase 2 Safety Data Q4 2021
Gastro-Intestinal Cancer
GOBLET
Tecentriq Multiple GI Cancers
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Enrolled Safety Run-ins Q1 2022
NU 18I01
Keytruda Pancreatic Cancer
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Phase 2 Data H1 2021
Multiple Myeloma
NCI-9603
Kyprolis R/R Multiple Myeloma
Preclinical Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started
Interim Data Achieved Q2 2020
WINSHIP 4398-18
Kyprolis + Opdivo R/R Multiple Myeloma
Preclinical Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started
Phase 1 Safety Data H1 2022

*Anti-PD-1 checkpoint inhibitor in development by Incyte (also known as INCMGA00012)